Banque Cantonale Vaudoise’s Filana Therapeutics FLNA Stock Holding History

Banque Cantonale Vaudoise’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,000	Closed	-$84K	–	1233
2022 Q3	$84K	Buy	+2,000	New	+$54K	﹤0.01%	910
2021 Q3	–	Sell	-10,000	Closed	-$854K	–	1348
2021 Q2	$854K	Buy	+10,000	New	+$536K	0.04%	464

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCM

Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Banque Cantonale Vaudoise's FLNA Position: Q4 2022 in Review

Banque Cantonale Vaudoise sold out of Filana Therapeutics (FLNA) in Q4 2022, closing a stake of 2,000 shares — an estimated $84K sold.

Banque Cantonale Vaudoise first reported a position in FLNA in Q2 2021 and held it in 2 quarters. The position peaked at $854K in Q2 2021. 153 funds tracked by Wall St. Rank hold FLNA as of Q4 2022.

Banque Cantonale Vaudoise reported no remaining Filana Therapeutics position as of Q4 2022 after selling out during the quarter.
Banque Cantonale Vaudoise sold 2,000 Filana Therapeutics shares in Q4 2022, an estimated $84K.
Banque Cantonale Vaudoise first reported a position in Filana Therapeutics in Q2 2021 and held it in 2 quarters.
Banque Cantonale Vaudoise's Filana Therapeutics position peaked at $854K in Q2 2021.
153 funds tracked by Wall St. Rank held Filana Therapeutics as of Q4 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q4 2022, filed 10 Feb 2023.